Health News

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies…

Read more

Filed under: Pharmacy News
Tags: cancer, gene, Genetic, medicine, Oncology, Pharmacy

Related posts

• Study links loss of PTEN gene with patient’s response to melanoma therapy (0)
  Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the [...]
  
  
• St. Jude finds more than 100 gene variations linked with response to leukemia treatment (0)
  Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this cancer. Read more [tags] Pharmacy News [/tags]
  
  
• Research finds more than 100 gene variations linked with response to leukemia treatment (0)
  Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this cancer. Read more [tags] Pharmacy News [/tags]
  
  
• New predictive medicine product for hereditary pancreatic and related cancers (0)
  Myriad Genetics, Inc. today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the [...]
  
  
• Epeius Biotechnologies’ REXIN-G, A Tumor-Targeted Genetic Medicine For Metastatic Cancer, Gains Phase 3 Product Designation From The U.S. FDA (0)
  Epeius Biotechnologies announced that the U.S. FDA has granted Phase 3 status for the Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek out and destroy metastatic cancer. According to Dr... Read more [tags] Pharmacy News [/tags]